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Abstract Homozygous mutations of the telomeric survival
motor neurone gene (SMN1) cause spinal muscular atrophy
(SMA). The centromeric copy gene (SMN2) generally skips
exon 7 during splicing and fails to compensate for SMN1
deficits, so SMA cells have reduced SMN protein and few
nuclear gems. To investigate the role of exon 7 in SMN
localisation, cDNAs for full-length SMN and SMNvexon 7 were
overexpressed in COS cells, neurones and SMA fibroblasts. Both
constructs formed discrete intranuclear bodies colocalising with
p80-coilin, but produced more cytoplasmic aggregates in cells
overexpressing exon 7. Hence, the exon 7 domain enhances SMN
aggregation but is not critical for gem formation. ß 2001 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
Key words: Spinal muscular atrophy; Survival motor neuron;
cDNA; Gem
1. Introduction
Spinal muscular atrophy (SMA) is caused by degeneration
of spinal cord motor neurones leading to muscle denervation
and atrophy. SMA is the second most common inherited le-
thal disorder of childhood and de¢ned as types I^III on the
basis of age at onset and disease severity [1^3]. The SMA
locus on chromosome 5q13 comprises two survival motor
neurone genes (SMN1 and SMN2) di¡ering by just 11 nucleo-
tides [4]. However, the critical nucleotide di¡erence occurs
within the exon 7 exonic splicing enhancer causing the copy
gene, SMN2, to skip exon 7 in up to 90% of transcripts [5,6].
Over 95% of 5q-linked SMA patients are homozygously de-
leted for SMN1 or have undergone gene conversion at exons 7
or 8, while the remainder have missense, nonsense or splice
site mutations [4,7^9]. SMN2 may be present in multiple cop-
ies and increasing copy number correlates with a milder phe-
notype in SMA. Indeed, one SMN1-deleted individual with
eight SMN2 copies remained almost asymptomatic in his
eighth decade [10]. Mice have only one SMN gene which, if
deleted, is lethal early in embryogenesis [11]. Although this is
rescued by expression of either human SMN1 or SMN2 in
transgenic embryos, it remains unclear in the case of SMN2
whether amelioration of SMA is due to full-length SMN2
transcripts generating residual intact protein or to a partially
deleted SMN protein derived from SMNv7 transcripts [12^
15].
Although SMN is expressed in many tissues, levels are par-
ticularly high in motor neurones, the cells principally a¡ected
in SMA. In the nucleus, SMN is associated with spliceosomal
proteins in aggregates known as gems, which may represent a
site for snRNP processing or transcriptosome assembly
[16,17]. These structures are closely associated with coiled
bodies (often called Cajal bodies) and it is possible that
gems and coiled bodies are identical. SMN is normally dif-
fusely distributed in the cytoplasm and is found in dendritic
and axonal processes of motor neurones [18^20].
In order to determine the in£uence of exon 7 on the sub-
cellular localisation of SMN, cDNAs corresponding to the
two principal SMN isoforms (SMN+exon7 and SMNvexon7)
were created and expressed as fusion proteins with green £uo-
rescent protein (GFP) or c-myc tags to distinguish them from
endogenous SMN. Expression of high levels of recombinant
SMN in COS cells, rat primary cortical neurones and ¢bro-
blasts from SMA type II patients demonstrated that gem for-
mation is not dependent on the exon 7 region of SMN and
that SMNv7 was able to restore gems in ¢broblasts from
SMN1-deleted patients. However, di¡erences between iso-
forms were observed in the cytoplasm.
2. Materials and methods
2.1. Reagents
All reagents were purchased from Sigma-Aldrich unless stated oth-
erwise. All restriction enzymes were purchased from New England
Biolabs.
2.2. Construction of cDNA vectors
A cDNA for the full coding region of human SMN1 (SMN+7) was
generated from human cells by RT-PCR, cloned into the vector
pGEM-T (Promega), then sub-cloned into pBluescript SK (Strata-
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gene) using SacII and HindIII restriction sites. Exon 7 was deleted by
PCR mutagenesis to create SMNv7 and the 3P stop codon eliminated
from both cDNAs to enable expression of 3P fusion proteins. BglII/
HindIII fragments of SMN cDNAs lacking a stop codon were cloned
into pCMVTag1 (Stratagene) to produce a C-terminal c-myc tag and
an N-terminal FLAG epitope. BglII/HindIII fragments of SMN
cDNAs retaining the stop codon were cloned into the pEGFP-C2
vector (Clontech) to express GFP at the N-terminus. Each construct
was sequenced using a di-rhodamine terminator cycle sequencing kit
and an ABI 377 sequencer (PE Applied Biosystems). Large quantities
of each of the vectors (c-myc-SMN+7, c-myc-SMNv7, GFP-SMN+7,
GFP-SMNv7) were prepared by maxiprep columns (Qiagen) for use
in transfections (Fig. 1A).
2.3. Cell culture and transfections
The simian kidney cell line COS-7 was grown in Dulbecco’s modi-
¢ed Eagle’s medium (DMEM)/10% foetal calf serum (FCS)/2 mM
L-glutamine (Life Technologies) with antibiotic/antimycotic. Cells
were plated on glass coverslips coated with 2% gelatin at 1U105
cells/well and transfected 24 h later using the cationic lipid reagent
DOSPER (1,3-dioleoyloxy-2-(6-carboxyspermyl)-propylamide; Roche
Diagnostics). Lipoplexes were formed by diluting 0.25 Wg plasmid
DNA in HEPES-bu¡ered saline and mixing with DOSPER in a ratio
(w:w) of 5:1 to a ¢nal volume of 5 Wl then added to wells containing
0.5 ml serum-free DMEM. After 4 h, this medium was replaced by
growth medium and cells incubated over a 6^40 h time course before
analysis.
Primary cortical neurone cultures were established from E16 rat
embryos. The cerebral cortex was dissected free from the meninges,
mechanically and enzymatically dissociated before being plated out
onto glass coverslips coated with poly-D-lysine and laminin. They
were grown in Neurobasal medium with B27 supplement containing
100 U/ml penicillin, 100 Wg/ml streptomycin and 2 mM L-glutamine
(all Life Technologies). After 7 days the cells were almost exclusively
neurones, staining positively for antibodies to neuro¢laments and
negative for glial ¢brillary acidic protein (Dako). Cultures were trans-
fected by calcium phosphate precipitation (Promega Profection kit)
using 10 Wg of plasmid DNA per well [21].
Human ¢broblasts were obtained from two independent patients
with SMA type II at the time of spinal surgery and cultured in
DMEM/20% FCS. These cells were transfected with GFP-SMN+7
and GFP-SMNv7 in DOSPER lipoplex complexes as above.
2.4. SDS^PAGE and Western blotting
Twenty-four hours post-transfection, COS cells were rinsed twice in
PBS and centrifuged at 13 000 rpm. Cell pellets were resuspended in
50 Wl SDS sample bu¡er (60 mM Tris^HCl pH 6.8, 2% SDS, 10%
glycerol, 0.05% bromophenol blue, 5% L-mercaptoethanol) and boiled
for 5 min. Lysates were run on a 10% polyacrylamide gel for 1.5 h at
120 V alongside a full-range Rainbow1 marker (Amersham Pharma-
cia) using the Bio-Rad Protean II system. Bands were then transferred
to a nitrocellulose ¢lter at 100 V for 1 h. Non-speci¢c antibody bind-
ing was blocked by a 1 h incubation with 5% non-fat dried milk in
Tris-bu¡ered saline containing 1% Tween 20 (TBS-T) then incubated
overnight at 4‡C with a mouse monoclonal anti-SMN antibody
(Transduction Laboratories), diluted 1:5000 in TBS-T/2% bovine se-
rum albumin/2% horse serum. After further washes in TBS-T and a
5 min block in TBS-T with 0.15% non-fat dried milk, the blot was
incubated for 1 h with a horseradish peroxidase-conjugated anti-
mouse antibody (Amersham Pharmacia; diluted 1:100) followed by
three 10 min washes in TBS-T. Bound antibody was detected using a
chemiluminescence system (Renaissance1 Western blot chemilumines-
cence reagent, NEN Life Science Products).
2.5. Immunocytochemistry
Cells were ¢xed for 5 min in 100% methanol at 320‡C, permeabi-
lised in PBS containing 1% NP40 and incubated for 1 h at room
temperature with primary antibodies to: (a) SMN exon 2 (mouse
monoclonal MANSMA1, a kind gift from Prof. Glenn Morris, North
East Wales Institute; 1:25); (b) c-myc (rabbit polyclonal primary
antibody A14 sc-789; Santa Cruz Biotechnology; 1:200); (c) p80-coi-
lin (rabbit polyclonal anti-p80 coilin, a kind gift from Prof. Angus
Lamond, University of Dundee; 1:350). Appropriate secondary anti-
bodies used were: biotinylated anti-mouse or anti-rabbit IgG (Amer-
sham-Pharmacia, 1:400), FITC-conjugated anti-rabbit IgG (Dako;
1:75), and streptavidin^Texas red for tertiary detection (Amersham-
Pharmacia, 1:400). In all cases, speci¢city of staining was con¢rmed
by omission of the primary antibody in controls. Stained cells were
mounted in £uorescence mounting medium (Dako) with 100 ng/ml
DAPI, visualised using a Zeiss Axioplan £uorescence microscope,
and photographed using a CCD digital camera with Smartcapture1
software.
Fig. 1. A: Design of expression vectors for expression of SMN+7
or SMNv7 cDNAs fused to either GFP or c-myc tags. B: Detection
of SMN in transfected COS cells by Western blot. Untransfected
cells express endogenous SMN (lane 1); cells transfected with c-
myc-SMN+7 (lane 2) and c-myc-SMNv7 (lane 3) showed a shift in
molecular weight in the upper band corresponding to loss of the
exon 7 domain; cells transfected with GFP-SMN+7 (lane 4) or
GFP-SMNv7 (lane 5) generated doublets showing a reduction in
size in the absence of the exon 7 domain.
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2.6. Quanti¢cation of SMN expression over time
Aggregates of recombinant SMN were counted according to GFP
or c-myc staining in the nucleus and cytoplasm, after set time intervals
ranging from 6 to 40 h. Twenty transfected cells were counted on each
coverslip and three to six coverslips were analysed per vector at each
time point. The mean numbers of aggregates in transfected cells were
calculated and analysed by Student’s t-test ( þ S.E.M., Fig. 4).
3. Results
3.1. Expression of SMN fusion proteins in COS-7 cells
All SMN constructs were transcribed from a CMV pro-
moter and contained an SV40 origin of replication, giving
relatively high expression levels in transfected COS cells
Fig. 2. Subcellular localisation of recombinant SMN in COS cells. High levels of recombinant SMN were detected by anti-SMN antibody
MANSMA1 relative to adjacent untransfected cells (b, d, f, h) and colocalised with their GFP (a, c) or c-myc (e, g) tags. The GFP tag ap-
peared to inhibit intranuclear localisation of SMN+7 (a, b). Greater numbers of intranuclear aggregates were observed in cells expressing
SMNv7 (c, d, g, h) relative to cells expressing full-length SMN (a, b, e, f), which expressed more cytoplasmic SMN. Magni¢cation U300.
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(Fig. 1A). Western blots probed with anti-SMN antibody de-
tected a prominent band at 44 kDa in cells transfected with
pCMVTag/SMN+7 and a slightly smaller band in cells trans-
fected with pCMVTag/SMNv7 (Fig. 1B). Samples transfected
with pGFP-SMN+7 and pGFP-SMNv7 showed doublets at
approximately 70 and 65 kDa respectively, probably re£ecting
conformational isoforms of the SMN-GFP fusion proteins.
Untransfected COS cell lysates revealed a band at approxi-
mately 38 kDa, representing endogenous SMN. This band
was also present in CMVTag-SMN and GFP-SMN lanes,
although the latter is unseen in Fig. 1B, as a greater dilution
of GFP-SMN lysates was employed to match exposures
across samples.
In COS cells transfected with GFP constructs, colocalisa-
tion of SMN and GFP expression (Fig. 2a^d) showed that
both full-length and v7 versions of SMN fused to GFP were
able to form intranuclear aggregates. Interestingly, a greater
number of nuclear aggregates were observed in cells trans-
fected with GFP-SMNv7 than in cells expressing GFP-
SMN+7 (26.7 þ 1.2/cell for GFP-SMNv7; 4.7 þ 1.2/cell for
GFP-SMN+7; t-test, P6 0.01), although overall expression
levels were similar. In order to test if this was an e¡ect of
the 27 kDa GFP moiety, cells were also transfected with
SMNv7 and SMN+7 linked to a much smaller (10 amino
acid) c-myc tag (Fig. 2e^h). Expression of c-myc-SMN+7 re-
stored large numbers of SMN aggregates to the nucleus, sug-
gesting that the GFP moiety may inhibit intranuclear trans-
port. Recombinant SMN proteins were also observed in the
cytoplasm both di¡usely and in large cytoplasmic aggregates.
At 24 h post-transfection, the number of cytoplasmic aggre-
gates was signi¢cantly greater in cells transfected with GFP-
SMN+7 and c-myc-SMN+7 (Fig. 2a,e; 46.9 þ 3.2 and
29.5 þ 0.5 respectively) relative to those expressing GFP-
SMNv7 and c-myc-SMNv7 (Fig. 2c,g; 3.9 þ 0.6 and 3 þ 0.7
respectively). Cells transfected with GFP constructs lacking
SMN showed only di¡use cytoplasmic and nuclear £uores-
cence (data not shown). Only faint cytoplasmic staining for
SMN and few gems were observed in untransfected COS cells.
3.2. Colocalisation of recombinant SMN with p80-coilin:
evidence of gem formation
COS cells transfected with either GFP-SMN+7 or GFP-
SMNv7 and immunolabelled with p80-coilin antibody dem-
onstrated a striking colocalisation typical of gems (Fig. 3).
Interestingly, the number of p80-positive aggregates was high-
er in cells transfected with SMN (Fig. 3C) compared to un-
Fig. 3. Colocalisation of GFP-SMN and p80-coilin in transfected nuclei. Cells transfected with either GFP-SMN+7 (A^C) or GFP-SMNv7
(D^F) were immunostained for p80-coilin (A, D). Rhodamine and green £uorescence images were merged (C, F) to show intranuclear colocali-
sation (yellow). Coilin staining in an untransfected cell is arrowed. Magni¢cation U270.
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transfected cells (Fig. 3C arrowed). This supports the idea
that gems and coiled bodies are associated structures and in-
creased expression of one component (SMN) leads to a cor-
responding increase in p80-coilin aggregation [17]. Consistent
with some other studies, occasional aggregates that were
SMN-positive but lacked coilin were observed, suggesting
that coiled bodies and gems are not identical [17].
3.3. Expression of recombinant SMN in transfected COS-7
cells over time
To further investigate observed di¡erences in the expression
of GFP-SMN and c-myc-SMN, a time course study was per-
formed for each of the four vectors (Fig. 4). GFP-SMN was
evident 6 h after transfection while c-myc-SMN was not ob-
served before 10 h. No di¡erences were seen between the onset
of expression of SMN+7 and SMNv7 for either vector. Peak
expression of both vectors occurred between 12 and 24 h post-
transfection.
Nuclear and cytoplasmic aggregates appeared concurrently
in all transfected cells. In cells expressing c-myc-SMN the
numbers of intranuclear aggregates were equivalent for
SMN+7 and SMNv7 proteins at each time point (17.1 þ 1.3
and 17.6 þ 2.1 respectively; t-test, Ps 0.8; Fig. 4a,b: 18 h
time point) indicating that nuclear targeting is not dependent
on the exon-7-derived region. However, c-myc-SMN+7-trans-
fected cells had signi¢cantly larger numbers of cytoplasmic
aggregates than c-myc-SMNv7-transfected cells (21.3 þ 1.3
compared to 4 þ 0.9; t-test, P6 0.05; Fig. 4a,b: 18 h time
point) providing evidence that the exon-7-derived region pro-
motes self-association. Consistent with this, cells expressing
GFP-SMN+7 demonstrated high levels of cytoplasmic expres-
sion relative to GFP-SMNv7 (Fig. 4c,d). A slight decrease in
the number of cytoplasmic aggregates over time can be seen
with both GFP-linked proteins, probably re£ecting loss of
episomal plasmid DNA.
3.4. SMN+7 and SMNv7 proteins form gems in cultured
primary neurones
To examine the subcellular expression of SMN in a cell type
relevant to SMA, GFP-SMN constructs were transfected into
Fig. 4. Time course of recombinant SMN expression in COS cells. Cells transfected with each construct were ¢xed at time points from 6 to
40 h and examined for green £uorescence or c-myc immuno£uorescence. Expression is represented as number of GFP- or c-myc-positive aggre-
gates per cell (nuclear or cytoplasmic). Error bars indicate S.E.M.
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Fig. 5. Expression of GFP-SMN in rat cortical neurone cultures. Phase contrast (A, D), SMN immunostaining (B, E) and green £uorescence
images (C, F) are shown. GFP-SMN+7 was mainly localised in the cytoplasm and dendrites (B, C) whereas SMNv7 was present in the nucleus
and cytoplasm (E, F). Magni¢cation U228.
Fig. 6. Expression of GFP-SMN in ¢broblasts from SMA type II patients. Green £uorescence (A, C) or immuno£uorescence (B, D) for re-
combinant SMN showed cytoplasmic and intranuclear aggregates in cells transfected with GFP-SMN+7 (A, B) and mainly intranuclear aggre-
gates in cells transfected with GFP-SMNv7 (C, D). Magni¢cation U228.
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primary rat cortical neurones (Fig. 5). In con¢rmation of our
¢ndings in COS cells the relative di¡erences in nuclear aggre-
gate formation between SMN+7 and SMNv7 were also ob-
served in these cells (Fig. 5C,F). Normally, rodents express
very little SMN in the cytoplasm, but cytoplasmic aggregates
of GFP-SMN+7 were found throughout the cell, including
along the dendrites and axon (Fig. 5B) as previously described
in vivo [18,20]. Indeed, while GFP-SMN+7 formed aggregates
preferentially in the cytoplasm, with a few visible nuclear
gems (Fig. 5B,C), GFP-SMNv7 formed numerous gems and
a more di¡use cytoplasmic expression pattern (Fig. 5E,F).
3.5. SMN+7 and SMNv7 restore gems in the nuclei of cells
from SMA patients
Fibroblast cultures were obtained from skin biopsies of two
patients with SMA type II and genetically con¢rmed absence
of SMN1. These cells were transfected with GFP-SMN+7 and
GFP-SMNv7 and immunolabelled for SMN 24 h later, when
they showed a substantial increase in nuclear gems relative to
untransfected cells (Fig. 6C,D). Consistent with earlier obser-
vations in COS cells and cortical neurones, both GFP-
SMN+7 (Fig. 6A,B) and GFP-SMNv7 (Fig. 6C,D) constructs
generated more nuclear gems in GFP-SMNv7-transfected
cells and large numbers of cytoplasmic aggregates in cells
transfected with GFP-SMN+7 (Fig. 6A,B).
4. Discussion
SMA is caused by motor neuronal dysfunction and cell
death associated with a critical reduction in SMN protein
levels. The precise function of SMN has not been identi¢ed,
but it is believed to play a part in the transport of spliceosome
components between the cytoplasm and nucleus [24,25]. SMN
and associated spliceosome components, such as hnRNP U,
are concentrated in intranuclear gems, which may be involved
in snRNP processing or transcriptosome assembly. Gems are
signi¢cantly reduced in number in SMA patients and are vir-
tually absent from cells of transgenic mice in which exon 7 has
been removed by gene targeting [12]. SMA patients normally
express low levels of SMN, but this has previously been
thought to arise from the minority of SMN2-derived tran-
scripts that retain exon 7 after splicing, although this has
never been unequivocally demonstrated. Several studies have
evaluated endogenous SMN expression in a variety of animal
and human tissues, demonstrating that endogenous levels of
SMNv7 are insu⁄cient to: (a) form gems and (b) support
motor neurone survival [17,19,22,23]. Here, however, we
have overexpressed recombinant SMN molecules with or
without the exon 7 region in COS cells, primary neurones,
and ¢broblasts from SMA type II patients in order to eval-
uate the e¡ect of high levels of di¡erent SMN isoforms on
subcellular expression patterns.
Our results demonstrate that recombinant SMN fused to
GFP or c-myc epitopes can form cytoplasmic and nuclear
aggregates which mirror the pattern of endogenous SMN.
Colocalisation with p80-coilin in the nucleus con¢rmed that
our recombinant SMN proteins formed structures consistent
with gems. In concordance with others, an increase in SMN
was associated with an increase in p80-coilin bodies, again
indicating that the recombinant versions of SMN expressed
in this study reproduce the behaviour of native protein [17].
Counter to expectation, we found that SMN lacking the exon
7 domain is capable of entering the nucleus and forming gems
when expressed at high levels. SMA patients with more than
two copies of SMN2 generally develop a milder phenotype
[10] and the lethal phenotype of SMN knockout mice is res-
cued by multiple copies of human SMN2 [15]. While this may
be due to higher levels of full-length SMN with increased
SMN copy number, it may suggest that SMNv7 protein is
also capable of ameliorating SMN de¢ciency. Frugier et al.
[12] showed a lack of gems in mice expressing only SMNv7 in
their motor neurones and suggested that this was due to an
inherent defect in nuclear targeting. This may be the case, but
these animals expressed SMN2 only at relatively low levels. In
future, expression of varying levels of recombinant SMN us-
ing a less powerful or inducible promoter system may identify
the minimum level of SMN required for gem formation.
Importantly, our observation of large numbers of recombi-
nant gems in transfected nuclei from rat neurones and SMA
patients demonstrates that normal expression patterns can be
restored to cells where endogenous SMN levels are much re-
duced. Furthermore, we have provided evidence that recombi-
nant SMNv7 associates with p80-coilin in a similar way to
endogenous SMN. This shows that the tra⁄cking of SMNv7
to the nucleus can occur and is not dependent on the presence
of SMN1, as supported by others [26]. Consistent with our
observations that intranuclear gems appear to accumulate
more readily with high levels of SMNv7, it is possible that
exon 7 may encode a nuclear export signal such that SMN+7
protein is in dynamic equilibrium between intranuclear gems
and transport into the cytoplasm. SMNv7 on the other hand
is capable of entering the nucleus but may be poorly exported
into the cytoplasm.
While much attention has been given to the presence or
absence of gems and their composition, many tissues express-
ing SMN do not have gems suggesting that SMN also has a
signi¢cant function in the cytoplasm [17]. Moreover, in hu-
man motor neurone cell bodies, staining in perikarya and
dendrites is a prominent feature [18]. Here we also observed
recombinant SMN in dendritic processes of transfected neu-
rones. Our observed di¡erences in cytoplasmic localisation of
the two isoforms may be consistent with di¡erences in their
ability to form oligomers via the exon 7 domain, a feature
that may in£uence disease severity in SMA [27]. Poorer
oligomerisation by recombinant SMNv7 may have led to
fewer cytoplasmic aggregates (Fig. 4). More recently, the
domain encoded by exon 2b has also been shown to medi-
ate self-association, perhaps aiding SMN binding to SIP1
[28].
In summary, we have shown that both full-length and exon
7-de¢cient SMN proteins can form intranuclear gems when
expressed at su⁄cient levels and that these molecules repro-
duce subcellular localisation patterns similar to endogenous
SMN in neuronal cultures and cells from SMA patients.
Our observations on the subcellular localisation of recombi-
nant SMN support the value of exploring gene transfer as a
therapeutic strategy in SMA.
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